News | December 31, 2025
Transcenta teams up with EirGenix to revolutionise biologics manufacturing
Transcenta will grant EirGenix a non-exclusive license to its Highly Intensified Continuous Bioprocessing (HiCB) platform
Transcenta will grant EirGenix a non-exclusive license to its Highly Intensified Continuous Bioprocessing (HiCB) platform
CIRRUS-HCM, an open-label, multi-part study, evaluates EDG-7500 in patients with obstructive and nonobstructive HCM
Tablets will be manufactured at Granules' US-based facility located in Chantilly, Virginia
The approval comes with 180 days of Competitive Generic Therapy (CGT) exclusivity,
This agreement will enhance Lupin’s gastroenterology portfolio and expand its presence in emerging markets
WINREVAIR is currently the first and only activin signalling inhibitor approved for PAH across all 27 EU member states
Senores Pharmaceuticals is poised to accelerate its presence in the Asia-Pacific region
The partnership targets breakthroughs in Alzheimer’s disease, diabetes, cancer, and cell and gene therapy
Health Canada’s approval was based on a comprehensive evaluation of analytical, nonclinical, and clinical data
The approval by the US FDA comes after extensive safety testing and manufacturing improvements
Subscribe To Our Newsletter & Stay Updated
